Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 3
2004 3
2005 4
2006 6
2007 8
2008 7
2009 11
2010 9
2011 9
2012 20
2013 30
2014 38
2015 40
2016 33
2017 27
2018 24
2019 29
2020 40
2021 38
2022 24
2023 24
2024 22
2025 9
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Results by year

Filters applied: . Clear all
Page 1
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, Thompson PD, Libby P, Cho L, Plutzky J, Bays HE, Moriarty PM, Menon V, Grobbee DE, Louie MJ, Chen CF, Li N, Bloedon L, Robinson P, Horner M, Sasiela WJ, McCluskey J, Davey D, Fajardo-Campos P, Petrovic P, Fedacko J, Zmuda W, Lukyanov Y, Nicholls SJ; CLEAR Outcomes Investigators. Nissen SE, et al. N Engl J Med. 2023 Apr 13;388(15):1353-1364. doi: 10.1056/NEJMoa2215024. Epub 2023 Mar 4. N Engl J Med. 2023. PMID: 36876740 Clinical Trial.
The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or coronary revascularization. ...CONCLUSIONS: Among statin-intolerant patients …
The primary end point was a four-component composite of major adverse cardiovascular events, defined as death from cardiovascular …
TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation.
Dreyfus J, Galloo X, Taramasso M, Heitzinger G, Benfari G, Kresoja KP, Juarez-Casso F, Omran H, Bohbot Y, Iliadis C, Russo G, Topilsky Y, Weber M, Nombela-Franco L, Sala A, Eixerés-Esteve A, Iung B, Obadia JF, Estevez Loureiro R, Riant E, Donal E, Hausleiter J, Badano L, Le Tourneau T, Coisne A, Modine T, Latib A, Praz F, Windecker S, Zamorano JL, von Bardeleben RS, Tang GHL, Hahn R, Webb J, Muraru D, Nejjari M, Chan V, De Bonis M, Carnero-Alcazar M, Nickenig G, Pfister R, Tribouilloy C, Rudolph V, Crestanello J, Lurz P, Bartko P, Maisano F, Bax J, Enriquez-Sarano M, Messika-Zeitoun D; TRIGISTRY investigators. Dreyfus J, et al. Eur Heart J. 2024 Feb 21;45(8):586-597. doi: 10.1093/eurheartj/ehad585. Eur Heart J. 2024. PMID: 37624856 Free article.
Renal denervation.
Drexel T, Bertog SC, Vaskelyte L, Sievert H. Drexel T, et al. Among authors: sievert h. Anadolu Kardiyol Derg. 2014 Mar;14(2):186-91. doi: 10.5152/akd.2014.5294. Epub 2014 Feb 11. Anadolu Kardiyol Derg. 2014. PMID: 24566514 Review.
Severe hypertension, resistant to conventional antihypertensive medications, is associated with major adverse cardiovascular and cerebrovascular events and renal insufficiency. Renal sympathetic nerve over-activity frequently accompanies essential hypertension. ...In the f …
Severe hypertension, resistant to conventional antihypertensive medications, is associated with major adverse cardiovascular and cere …
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.
Pristipino C, Sievert H, D'Ascenzo F, Louis Mas J, Meier B, Scacciatella P, Hildick-Smith D, Gaita F, Toni D, Kyrle P, Thomson J, Derumeaux G, Onorato E, Sibbing D, Germonpré P, Berti S, Chessa M, Bedogni F, Dudek D, Hornung M, Zamorano J; Evidence Synthesis Team; Eapci Scientific Documents and Initiatives Committee; International Experts. Pristipino C, et al. Among authors: sievert h. Eur Heart J. 2019 Oct 7;40(38):3182-3195. doi: 10.1093/eurheartj/ehy649. Eur Heart J. 2019. PMID: 30358849 Free article. Review.
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. Holmes DR Jr, et al. Among authors: sievert h. J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029. J Am Coll Cardiol. 2014. PMID: 24998121 Free article. Clinical Trial.
RESULTS: At 18 months, the rate of the first coprimary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular/unexplained death) was 0.064 in the device group versus 0.063 in the control group (rate ratio 1.07 [95% credible interval (CrI): 0.57 …
RESULTS: At 18 months, the rate of the first coprimary efficacy endpoint (composite of stroke, systemic embolism [SE], and cardiovascular …
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.
Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, Kar S, Swarup V, Gordon N, Holmes D; PROTECT AF Steering Committee and Investigators. Reddy VY, et al. Among authors: sievert h. JAMA. 2014 Nov 19;312(19):1988-98. doi: 10.1001/jama.2014.15192. JAMA. 2014. PMID: 25399274 Clinical Trial.
Patients in the device group demonstrated lower rates of both cardiovascular mortality (1.0 events per 100 patient-years for the device group [17/463 patients, 3.7%] vs 2.4 events per 100 patient-years with warfarin [22/244 patients, 9.0%]; hazard ratio [HR], 0.40; 95% CI, …
Patients in the device group demonstrated lower rates of both cardiovascular mortality (1.0 events per 100 patient-years for the devi …
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation.
Doshi SK, Kar S, Nair DG, Waggoner T, Agarwal H, Moussavian M, Kashani A, Oza S, Feldman L, Sadhu A, DeLurgio D, Alli O, Nielsen-Kudsk JE, Yamamoto M, Alkhouli M, Camm AJ, Coylewright M, Gibson CM, Granger CB, Gurol ME, Huber KC, Mansour M, Natale A, Pocock SJ, Reddy VY, Saliba WI, Asch FM, Wehrenberg S, Frost K, Christen T, Sutton BS, Stein KM, Leon MB, Ellenbogen KA; CHAMPION-AF Investigators. Doshi SK, et al. N Engl J Med. 2026 Jun 4;394(21):2083-2094. doi: 10.1056/NEJMoa2517213. Epub 2026 Mar 28. N Engl J Med. 2026. PMID: 41910347 Clinical Trial.
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for noninferiority (noninferiority margin, 4.8 percentage points) after 3 years of follow-up. ...CONCLUSIONS: Among patients with atrial fibrillation …
The primary efficacy end point - a composite of death from cardiovascular causes, stroke, or systemic embolism - was tested for nonin …
Transcatheter left ventriculoplasty.
Spilias N, Howard TM, Anthony CM, Laczay B, Soltesz EG, Starling RC, Sievert H, Estep JD, Kapadia SR, Puri R. Spilias N, et al. Among authors: sievert h. EuroIntervention. 2023 Apr 24;18(17):1399-1407. doi: 10.4244/EIJ-D-22-00544. EuroIntervention. 2023. PMID: 37092265 Free PMC article. Review.
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P; PROTECT AF Investigators. Holmes DR, et al. Among authors: sievert h. Lancet. 2009 Aug 15;374(9689):534-42. doi: 10.1016/S0140-6736(09)61343-X. Lancet. 2009. PMID: 19683639 Clinical Trial.
Efficacy was assessed by a primary composite endpoint of stroke, cardiovascular death, and systemic embolism. We selected a one-sided probability criterion of non-inferiority for the intervention of at least 97.5%, by use of a two-fold non-inferiority margin. ...
Efficacy was assessed by a primary composite endpoint of stroke, cardiovascular death, and systemic embolism. We selected a one-sided …
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair.
Brener MI, Lurz P, Hausleiter J, Rodés-Cabau J, Fam N, Kodali SK, Rommel KP, Muntané-Carol G, Gavazzoni M, Nazif TM, Pozzoli A, Alessandrini H, Latib A, Biasco L, Braun D, Brochet E, Denti P, Lubos E, Ludwig S, Kalbacher D, Estevez-Loureiro R, Connelly KA, Frerker C, Ho EC, Juliard JM, Harr C, Monivas V, Nickenig G, Pedrazzini G, Philippon F, Praz F, Puri R, Schofer J, Sievert H, Tang GHL, Andreas M, Thiele H, Unterhuber M, Himbert D, Alcázar MU, Von Bardeleben RS, Windecker S, Wild MG, Maisano F, Leon MB, Taramasso M, Hahn RT. Brener MI, et al. Among authors: sievert h. J Am Coll Cardiol. 2022 Feb 8;79(5):448-461. doi: 10.1016/j.jacc.2021.11.031. J Am Coll Cardiol. 2022. PMID: 35115101 Free article.
417 results